IV Immune Globulin Bests Placebo for Dermatomyositis
WEDNESDAY, Oct. 5, 2022 (HealthDay News) -- Significantly more adults with dermatomyositis receiving intravenous immune globulin (IVIG) versus placebo have a response of at least minimal improvement, according to a study published in the Oct. 6 issue of the New…